AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03303079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 or placebo
Description: TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
Study NCT03303079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be subcutaneously administered once monthly for 3 months.
Study NCT02208453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSpace Implantation
Description: InSpace device Implantation
Study NCT01095653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5 mg, Once daily, 24 weeks
Study NCT01095653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, 24 weeks
Study NCT01095653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
Study NCT01174927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diacetylmorphine (DAM)
Description: The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
Study NCT01174927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02237859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
Study NCT02237859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fruit juice/placebo
Description: Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
Study NCT01782859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT01782859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Study NCT01782859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Prednisone)
Study NCT02680912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm needle acupuncture
Description: There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
Study NCT02680912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle acupuncture
Description: The point selection protocol will be exactly the same as the experimental group
Study NCT03097874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment
Description: Family Based Treatment of adolescent Anorexia Nervosa
Study NCT03097874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment + Intensive Parental Coaching
Description: Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
Study NCT02360956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil tablets
Description: Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
Study NCT02360956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive medication (per doctor suggestion)
Description: Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
Study NCT00571987 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)
Description: Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
Study NCT01095653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Placebo
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks
Study NCT00138476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
Study NCT00138476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk Virus
Description: Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.
Study NCT02978105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-conditioning techniques
Description: Self-hypnosis to increase self-control before meals and every food compulsion episode
Study NCT00067366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral treatment
Description: Cognitive-Behavioral skills training for chronic pain
Study NCT00067366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention and lifestyle counseling
Description: Attention and lifestyle counseling added to Standard Care
Study NCT02069743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePAL Mobile Application
Description: A mobile application designed to help cancer patients better self-manage cancer pain.
Study NCT01626560 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daptomycin
Description: daptomycin 4-6mg/kg qd 10 - 14 days
Study NCT01626560 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin
Description: Vancomycin 1g q12h 10 - 14 days
Study NCT02282670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5204
Study NCT02282670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stillen tab.
Study NCT03535870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device
Study NCT03535870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder
Description: Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
Study NCT03535870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo dry powder administered via the LOMI inhaler device
Study NCT01111149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill created and masked by the pharmacy to be used as a control.
Study NCT01111149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
Study NCT01111149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion HCl
Description: in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
Study NCT03020680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
Study NCT03020680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
Study NCT00938379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% deet insect repellent
Description: skin-applied repellent lotion
Study NCT02978105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care (diet, exercise and behavioral therapy)
Description: dietary recommendations, exercise recommendations, and behavioral recommendations
Study NCT00399685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-Cyclen LO
Description: Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
Study NCT00938379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: Identical base formulation of lotion but without any deet active
Study NCT03032666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir
Description: treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
Study NCT03835611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game based treadmill Platform
Description: The protocol for the intervention group will be:~* Warm up exercised consisting of rhythmical large movements (10minutes)~* Dynamic standing balance training by playing commercial games with head rotations while standing on a compliant surface to increase balance demands. (10 Minutes)~* DT treadmill training, consisting of playing commercial computer games while walking on the treadmill at a self-selected comfortable speed. Participants will be allowed to take rest when required and total effective DT treadmill walking will be for 30minutes. Treadmill speed will be aimed to progress depending on participant performance and documented. An overhead safety harness will always be provided to participants while walking on the treadmill. (25minutes)
Study NCT03835611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: * Warm-up exercise consisting of rhythmical large movements (10 minutes).~* Core standing balance exercises on a sponge surface (10 minutes).~* Treadmill walking for 20 minutes, which includes rests periods... An overhead safety harness will be provided to participants while walking on the treadmill~* Overground walking in an obstacle course. Participants will be instructed to walk along a curved path (marked by tape) and avoid obstacles placed randomly. The obstacle will be thin sponge pads with 10-12 inches in diameter (15minutes).
Study NCT03296657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride
Description: subjects will brush with paste twice daily for 2 weeks
Study NCT00399685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen
Description: Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
Study NCT00399685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen + Efavirenz
Description: Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
Study NCT02978105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care (diet, exercise and behavioral therapy)
Description: dietary recommendations, exercise recommendations, and behavioral recommendations
Study NCT02674282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Description: ACL reconstruction with hamstrings autograft.
Study NCT02670707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 100 mg/m\^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
Study NCT02670707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine/prednisone
Description: Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m\^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m\^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m\^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day
Study NCT04612660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on cervical cancer prevetnion
Description: Motivational group education by trained bilingual community health educators (CHEs) on cervical cancer prevention
Study NCT04612660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic group interaction
Description: Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
Study NCT04612660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician engagement
Description: Engaging community bilingual physicians in cervical cancer screening and referral;
Study NCT02745795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
Study NCT02745795 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Conventional Interview
Description: Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
Study NCT01812395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy using harmonic focus (r)
Description: Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
Study NCT01812395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional thyroidectomy
Description: Vessels are ligated with sutures then cut using classic scalpel or scissors.
Study NCT00399685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen
Description: Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
Study NCT03067337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stainless Steel Crown (Group A)
Description: Full coverage restoration for multi-surface carious teeth
Study NCT03067337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuSmile Zirconia Crowns (Group B)
Description: Full coverage restoration for multi-surface carious teeth
Study NCT02064647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trend Arrow Adjustment Tool
Description: The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
Study NCT02064647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10/20% bolus adjustment
Description: The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
Study NCT04942288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The first group is acupressure and massage, the second group is massage
Description: In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.
Study NCT01524497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 75mg tablet/150 mg tablet
Study NCT03410940 — intervention group
Intervention type: DEVICE
Intervention: CLS Brevius stem with Kinectiv technology
Study NCT02982850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Study NCT02982850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Study NCT02982850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT01337947 — intervention group
Intervention type: DRUG
Intervention: Definity microbubbles
Description: Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
Study NCT03523754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isosorbide Mononitrate 40 MG to study group
Description: Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening \& induction of labor in study group
Study NCT03958799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation B
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT03958799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation C
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT04612660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patient navigation assistance will be provided to participants who tested HPV positive for further diagnostic testing and treatment.
Study NCT03958799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation A
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT03958799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Tdap vaccine Formulation D
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT03958799 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tdap vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT02766062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: metabolic syndrome
Description: metabolic syndrome
Study NCT04612660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Description: general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
Study NCT01356342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S 2010-2011, inactivated
Description: The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections
Study NCT01065948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous glucose monitoring device
Description: monitor interstitial glucose level every 5 min over 4 hours
Study NCT03190265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
Study NCT03190265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
Study NCT03190265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
Study NCT03190265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
Study NCT03190265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.